MICROSAIC SYSTEMS PLC

Investor Presentation • Jan 11, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8124M

Microsaic Systems plc

11 January 2019

11 January 2019

Microsaic Systems plc

("Microsaic" or the "Company")

Microsaic announces new protein identification product

Microsaic Systems plc (AIM: MSYS), the developer of point of need mass spectrometry ("MS") instruments, announces the introduction of its new protein identification technology.

The Microsaic MiD® ProteinID is a break-through mass identification technique that allows users to verify target proteins throughout the whole bioprocessing value chain. By providing deterministic characterisation for proteins and small molecules at the point of need, the Microsaic MiD® ProteinID offers fast results over a mass range of 50-3,200 m/z, the broadest mass coverage for a small footprint mass spectrometer. Driven by design, the Microsaic MiD® ProteinID is transformational for process analytics, as its abilities as a point-of-need technology are derived from simplicity, and low maintenance which allows for minimal down-time and greater confidence in results.

Biologic drugs represented eight out of ten top selling drugs in 2016, with expected revenues in 2019 of c$445Bn. Revenues are c$15Bn from the top eight suppliers of manufacturing equipment into this industry.

Biologic manufacture demands real-time analysis throughout the entire process. The Microsaic MiD® ProteinID provides real time analysis from the raw in-coming goods, to upstream 'in-cell' drug production, and subsequent downstream product purification.

The Microsaic MiD® ProteinID was ranked among the top innovative products of the year by The Analytical Scientist Innovation Awards in December 2018.

Glenn Tracey, CEO of Microsaic, commented, "Bringing the power of the centralised laboratory to in-situ bioprocessing line measurements, the Microsaic MiD® ProteinID reduces key bioprocessing analyses from days to minutes. This means that operators can monitor feedstocks, metabolites and target proteins in just one measurement, thus accelerating time-to-market for new biologics development. Mass spectrometry can now offer superlative performance to high value manufacturing industries at the point-of-need, providing much greater insights over ubiquitous optical sensors."

Enquiries:
Microsaic Systems plc Glenn Tracey, CEO Bevan Metcalf, FD	+44 (0) 1483 751 577
N+1 Singer (Nominated Adviser & Broker) Shaun Dobson / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	+44 (0)20 7496 3000
IFC Advisory Ltd (Financial PR) Graham Herring Heather Armstrong Florence Chandler	+44 (0)20 3934 6630

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing.  The Company works with established global life science companies to co-develop new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines.  MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

The Microsaic's compact MiD® MS systems retain the functionality of larger conventional MS systems, while being easier to use by non-specialists, and consume less energy and have lower running costs. For more information, please go to www.microsaic.com.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAURRWRKBAAAAR